The Patent Finder

Terms ending in 2029

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 7,988,973Activin-Actrii Antagonists and Uses for Increasing Red Blood Cell Levels
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 8,293,238GDF3 Antibodies and Related Methods
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 8,158,584Pharmaceutical Preparations Comprising an ALK1-FC Fusion Protein
In force
 · High confidence
Ludwig Institute for Cancer Research Ltd.In forceHigh confidence
US 8,173,601Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 8,216,997Methods for Increasing Red Blood Cell Levels and Treating Anemia Using a Combination of GDF Traps and Erythropoietin Receptor Activators
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 8,361,957An Isolated GDF Trap Polypeptide
In force
 · High confidence
Acceleron Pharma, Inc.In forceHigh confidence
US 8,703,927Isolated Nucleotide Sequences Encoding GDF Traps
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,439,945Isolated Nucleotide Sequences Encoding GDF Traps
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,505,813Use of GDF Traps to Treat Anemia
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 9,932,379Isolated Nucleotide Sequences Encoding GDF Traps
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
9 more term ends in 2029 · Pro
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
Upgrade to Pro
18 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited